NUMINUS WELLNESS INC (NUMI.CA) Fundamental Analysis & Valuation
TSX:NUMI • CA67054W1032
Current stock price
0.05 CAD
+0.02 (+42.86%)
Last:
This NUMI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NUMI.CA Profitability Analysis
1.1 Basic Checks
- In the past year NUMI has reported negative net income.
- NUMI had a negative operating cash flow in the past year.
- In the past 5 years NUMI always reported negative net income.
- NUMI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- NUMI's Return On Assets of -213.24% is on the low side compared to the rest of the industry. NUMI is outperformed by 90.91% of its industry peers.
- NUMI has a Return On Equity of -644.74%. This is amonst the worse of the industry: NUMI underperforms 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -213.24% | ||
| ROE | -644.74% | ||
| ROIC | N/A |
ROA(3y)-79.64%
ROA(5y)-255.28%
ROE(3y)-118.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of NUMI (32.02%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of NUMI has grown nicely.
- The Profit Margin and Operating Margin are not available for NUMI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.27%
GM growth 5YN/A
2. NUMI.CA Health Analysis
2.1 Basic Checks
- NUMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for NUMI has been increased compared to 1 year ago.
- The debt/assets ratio for NUMI is higher compared to a year ago.
2.2 Solvency
- NUMI has an Altman-Z score of -13.73. This is a bad value and indicates that NUMI is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -13.73, NUMI is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.95 indicates that NUMI is somewhat dependend on debt financing.
- NUMI has a Debt to Equity ratio of 0.95. This is in the lower half of the industry: NUMI underperforms 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.73 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
- NUMI has a Current Ratio of 1.40. This is a normal value and indicates that NUMI is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of NUMI (1.40) is comparable to the rest of the industry.
- NUMI has a Quick Ratio of 1.40. This is a normal value and indicates that NUMI is financially healthy and should not expect problems in meeting its short term obligations.
- With a decent Quick ratio value of 1.40, NUMI is doing good in the industry, outperforming 60.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 |
3. NUMI.CA Growth Analysis
3.1 Past
- NUMI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.67%, which is quite impressive.
- NUMI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.69%.
- NUMI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 197.54% yearly.
EPS 1Y (TTM)37.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.87%
Revenue 1Y (TTM)22.69%
Revenue growth 3Y197.54%
Revenue growth 5YN/A
Sales Q2Q%-27.88%
3.2 Future
- Based on estimates for the next years, NUMI will show a very strong growth in Earnings Per Share. The EPS will grow by 29.53% on average per year.
- Based on estimates for the next years, NUMI will show a very strong growth in Revenue. The Revenue will grow by 22.63% on average per year.
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y25.99%
EPS Next 5Y29.53%
Revenue Next Year-18.04%
Revenue Next 2Y-0.45%
Revenue Next 3Y11.96%
Revenue Next 5Y22.63%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. NUMI.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NUMI. In the last year negative earnings were reported.
- Also next year NUMI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NUMI's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.44%
EPS Next 3Y25.99%
5. NUMI.CA Dividend Analysis
5.1 Amount
- NUMI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUMI.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:NUMI (1/29/2025, 7:00:00 PM)
0.05
+0.02 (+42.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-13 2025-01-13
Earnings (Next)N/A N/A
Inst Owners2.66%
Inst Owner ChangeN/A
Ins Owners3.55%
Ins Owner ChangeN/A
Market Cap16.12M
Revenue(TTM)26.05M
Net Income(TTM)-29.86M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.62 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.48 | ||
| P/tB | 3.48 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.08
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -213.24% | ||
| ROE | -644.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.02% | ||
| FCFM | N/A |
ROA(3y)-79.64%
ROA(5y)-255.28%
ROE(3y)-118.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.27%
GM growth 5YN/A
F-Score2
Asset Turnover1.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.51% | ||
| Cap/Sales | 0.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z | -13.73 |
F-Score2
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)61.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)21.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.87%
EPS Next Y58.33%
EPS Next 2Y38.44%
EPS Next 3Y25.99%
EPS Next 5Y29.53%
Revenue 1Y (TTM)22.69%
Revenue growth 3Y197.54%
Revenue growth 5YN/A
Sales Q2Q%-27.88%
Revenue Next Year-18.04%
Revenue Next 2Y-0.45%
Revenue Next 3Y11.96%
Revenue Next 5Y22.63%
EBIT growth 1Y24.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.26%
OCF growth 3YN/A
OCF growth 5YN/A
NUMINUS WELLNESS INC / NUMI.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NUMINUS WELLNESS INC (NUMI.CA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to NUMI.CA.
What is the valuation status of NUMINUS WELLNESS INC (NUMI.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to NUMINUS WELLNESS INC (NUMI.CA). This can be considered as Overvalued.
What is the profitability of NUMI stock?
NUMINUS WELLNESS INC (NUMI.CA) has a profitability rating of 1 / 10.
How financially healthy is NUMINUS WELLNESS INC?
The financial health rating of NUMINUS WELLNESS INC (NUMI.CA) is 2 / 10.